TimesSquare Capital Management LLC Decreases Holdings in DexCom, Inc. (NASDAQ:DXCM)

TimesSquare Capital Management LLC trimmed its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 7.0% in the first quarter, Holdings Channel reports. The firm owned 714,680 shares of the medical device company’s stock after selling 53,910 shares during the period. DexCom makes up 1.4% of TimesSquare Capital Management LLC’s portfolio, making the stock its 13th biggest position. TimesSquare Capital Management LLC’s holdings in DexCom were worth $99,126,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the business. DSM Capital Partners LLC bought a new position in shares of DexCom in the fourth quarter valued at approximately $28,000. Valley National Advisers Inc. boosted its holdings in shares of DexCom by 73.0% in the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 103 shares in the last quarter. Riverview Trust Co bought a new position in shares of DexCom in the first quarter valued at approximately $32,000. MV Capital Management Inc. boosted its holdings in shares of DexCom by 99.3% in the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 138 shares in the last quarter. Finally, Smithfield Trust Co boosted its holdings in shares of DexCom by 103.1% in the fourth quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock valued at $40,000 after acquiring an additional 165 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other DexCom news, EVP Michael Jon Brown sold 659 shares of the stock in a transaction that occurred on Friday, June 28th. The shares were sold at an average price of $114.29, for a total value of $75,317.11. Following the completion of the sale, the executive vice president now owns 66,901 shares in the company, valued at approximately $7,646,115.29. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, Director Bridgette P. Heller sold 1,000 shares of the stock in a transaction on Friday, June 14th. The shares were sold at an average price of $113.55, for a total transaction of $113,550.00. Following the transaction, the director now owns 25,349 shares in the company, valued at approximately $2,878,378.95. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Michael Jon Brown sold 659 shares of the stock in a transaction on Friday, June 28th. The stock was sold at an average price of $114.29, for a total transaction of $75,317.11. Following the transaction, the executive vice president now owns 66,901 shares in the company, valued at approximately $7,646,115.29. The disclosure for this sale can be found here. Insiders sold a total of 6,102 shares of company stock worth $755,103 in the last quarter. 0.30% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Raymond James increased their price objective on shares of DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a report on Friday, April 26th. UBS Group raised their target price on shares of DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Stifel Nicolaus reduced their target price on shares of DexCom from $145.00 to $132.00 and set a “buy” rating for the company in a report on Friday. Canaccord Genuity Group raised their target price on shares of DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a report on Friday, April 26th. Finally, StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a report on Monday, June 10th. Four analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $139.47.

DexCom Trading Up 1.2 %

Shares of NASDAQ:DXCM traded up $1.40 during mid-day trading on Friday, hitting $114.06. The stock had a trading volume of 2,300,403 shares, compared to its average volume of 2,489,635. The company has a debt-to-equity ratio of 1.08, a quick ratio of 2.53 and a current ratio of 2.90. The company has a market cap of $45.36 billion, a PE ratio of 73.59, a P/E/G ratio of 2.75 and a beta of 1.16. DexCom, Inc. has a 12-month low of $74.75 and a 12-month high of $142.00. The company’s 50 day moving average is $119.53 and its 200-day moving average is $124.97.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. DexCom had a net margin of 16.82% and a return on equity of 31.01%. The company had revenue of $921.00 million during the quarter, compared to the consensus estimate of $911.20 million. On average, sell-side analysts predict that DexCom, Inc. will post 1.78 EPS for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.